Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

Clinical trial NCT05103631 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05103631
Sponsor: Baylor College of Medicine
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Liver Cell Carcinoma Solid Tumor Wilms Tumor Malignant Rhabdoid Tumor Yolk Sac Tumor Rhabdomyosarcoma Liposarcoma Embryonal Sarcoma of the Liver

Start date: 2021-06-17
Primary completion: 2025-01-13
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.